Ken Itrato
Overview
Ken Itrato is a valued and experienced advisor to his clients in addressing a wide range of transactional, financing, and strategic business issues.
He handles a wide range of strategic and funding transactions, including venture capital, private equity, angel financing, and debt and also has a strong mergers and acquisitions practice. As a trusted team member, Ken advises clients with respect to the legal implications of their day-to-day operations, from complex customer and supplier relationships to employment and equity compensation. He effectively counsels on mission-critical licensing and partnering transactions involving core assets, technologies and/or products.
Career & Education
- General corporate and transactional law, AmLaw 50 firmGeneral corporate and transactional law, AmLaw 200 firm
- Cornell University, B.A.
- Georgetown University Law Center, J.D., Order of the Coif
- Massachusetts
Ken's Insights
Client Alert | 6 min read | 07.22.25
The One Big Beautiful Bill Act Expands Favorable QSBS Treatment
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “Act”), after it was passed by Congress on July 3, 2025. Notably, the Act made significant and welcome changes from the perspective of startup company stockholders and venture capital investors to the qualified small business stock (“QSBS”) rules set forth in Internal Revenue Code (“Code”) Section 1202. In a nutshell, the changes modernize (by adjusting for inflation) and expand the already favorable tax treatment for QSBS under Code Section 1202. The Act also permanently reinstates elective expensing for qualifying domestic research and experimental expenditures that will likely help more startups in research and capital intensive sectors qualify for favorable QSBS treatment.
Press Coverage | 07.17.25
Press Coverage | 06.20.25
Representative Matters
Ken's professional experience encompasses a range of representative matters during his tenure at Faber Daeufer & Itrato PC, prior to his transition to Crowell Life Sciences in 2025. Representative matters include:
- A 25+ year history of equity financings of life sciences organizations including therapeutics companies, biopharmaceutical companies, biotechnology companies, technology companies, and energy companies.
- A 25+ year history of investor-side equity financings on behalf of therapeutics companies, biopharmaceutical companies, biotechnology companies, and technology companies.
- Numerous investments from various venture capital firms and family offices into undisclosed portfolio companies.
- Numerous project financings by private investors on behalf of various companies, and clients by Silicon Valley Bank.
- Numerous strategic transactions, including advising biopharmaceutical, biotechnology, and technology clients across private and public acquisitions, sales or options.
Ken's Insights
Client Alert | 6 min read | 07.22.25
The One Big Beautiful Bill Act Expands Favorable QSBS Treatment
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “Act”), after it was passed by Congress on July 3, 2025. Notably, the Act made significant and welcome changes from the perspective of startup company stockholders and venture capital investors to the qualified small business stock (“QSBS”) rules set forth in Internal Revenue Code (“Code”) Section 1202. In a nutshell, the changes modernize (by adjusting for inflation) and expand the already favorable tax treatment for QSBS under Code Section 1202. The Act also permanently reinstates elective expensing for qualifying domestic research and experimental expenditures that will likely help more startups in research and capital intensive sectors qualify for favorable QSBS treatment.
Press Coverage | 07.17.25
Press Coverage | 06.20.25
Insights
Ken's Insights
Client Alert | 6 min read | 07.22.25
The One Big Beautiful Bill Act Expands Favorable QSBS Treatment
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (the “Act”), after it was passed by Congress on July 3, 2025. Notably, the Act made significant and welcome changes from the perspective of startup company stockholders and venture capital investors to the qualified small business stock (“QSBS”) rules set forth in Internal Revenue Code (“Code”) Section 1202. In a nutshell, the changes modernize (by adjusting for inflation) and expand the already favorable tax treatment for QSBS under Code Section 1202. The Act also permanently reinstates elective expensing for qualifying domestic research and experimental expenditures that will likely help more startups in research and capital intensive sectors qualify for favorable QSBS treatment.
Press Coverage | 07.17.25
Press Coverage | 06.20.25